AbbVie received final approval from the European Commission for its acquisition of Allergan.
Citing market conditions, Bausch Health made a series of moves to keep its debt at current levels.
A Utah gastroenterologist has agreed to pay the HHS’ Office of Civil Rights $100,000 for a corrective action plan related to a potential violation of a HIPAA security rule.
Takeda Pharmaceuticals continued to combat its Shire acquisition-related debt by selling off non-core assets to Hypera in Brazil. Takeda then dipped into its pool of non-core assets again and sold $660 million to Stada Arzneimittel.
On top of that, Takeda reached a deal to acquire PvP Biologics after the company reports results from its phase 1 proof-of-mechanism study of its treatment for uncontrolled celiac disease.
The FDA awarded Pavmed’s EsoGuard Esophageal DNA Test breakthrough device designation to aid in diagnosing Barrett’s esophagus.
Orlando, Fla.-based Digestive and Liver Center of Florida implemented AndorHealth’s ThinkAndor, an internal communication and collaboration tool that interprets EHR systems and presents information in a more easily interpretable format.
More articles on surgery centers:
3 ways to improve ASC revenue cycle performance
Indiana legislators meet resistance on price transparency bill
Maximizing reimbursements in ASCs: A review of reimbursement methodology
